Daxor allocates $1.9M of May 2023 offering proceeds to optical blood volume analyzer development

DAXOR CORP

Net proceeds of $3,555,532 from 410,260 shares at $9.75/share in May 2023 public offering.
$1,900,000 reserved for next-generation optical blood volume analyzer systems development.
Development expected over 24 months in conjunction with Department of Defense technology efforts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.